S&P Capital IQ Reacts to Recent News About J.P. Morgan Chase & Co. Chairman/CEO

In a report published Wednesday, S&P Capital IQ analyst S. Kessler reiterated a Buy rating and $66.00 price target on

. In the report, S&P Capital IQ noted, “We keep our 12-month target price of $66, 10.8X our EPS estimate for the next four quarters of $6.10. JPM announces that Chairman and CEO Jamie Dimon is being treated for throat cancer, which was apparently caught early and is seen as being treatable. Mr. Dimon expects to be actively involved in the leadership of the company during the treatment period. While we view this as a clear negative for JPM, especially considering Mr. Dimon's role and reputation as an important industry leader, we also see these circumstances as manageable for JPM.” J.P. Morgan Chase & Co. closed on Tuesday at $57.57.